Bellerophon Therapeutics Balance Sheet Health
Financial Health criteria checks 4/6
Bellerophon Therapeutics has a total shareholder equity of $5.6M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $11.2M and $5.6M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
Interest coverage ratio | n/a |
Cash | US$10.58m |
Equity | US$5.62m |
Total liabilities | US$5.62m |
Total assets | US$11.25m |
Recent financial health updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 6L7A's short term assets ($11.2M) exceed its short term liabilities ($5.6M).
Long Term Liabilities: 6L7A has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: 6L7A is debt free.
Reducing Debt: 6L7A has not had any debt for past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 6L7A has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: 6L7A has less than a year of cash runway if free cash flow continues to reduce at historical rates of 3.7% each year